相关实验视频

Updated: Jul 22, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

在 NIR-II 聚合诱导的排放声敏化剂,用于在膀癌症中诱导热致死

Meixin Shan^1,2, Xinwei Wang³, Zhu Wang⁴

¹School of Chemistry and Environmental Engineering, Changchun University of Science and Technology, Changchun, 130022, PR China.

Bioactive materials

|February 24, 2026

概括

这项研究介绍了BBTPA,这是一种用于声动疗 (SDT) 的新型聚合诱导排放 (AIE) 声敏化剂. BBTPA纳米粒子有效地产生反应性氧物种 (ROS),诱导癌细胞死亡并增强抗瘤免疫力.

科学领域:

生物医学工程生物医学工程
材料科学材料科学材料科学
在瘤学瘤学.

背景情况:

超声波疗法 (SDT) 提供了使用超声波和超声波敏感剂的向癌症治疗.
传统的声敏化剂受到聚合引起的火 (ACQ) 的影响,限制了活性氧物种 (ROS) 的产生.
需要新的声敏剂来克服ACQ并提高SDT的疗效.

研究的目的:

开发一种基于乙的新型声敏化剂,具有聚合诱导排放 (AIE) 特性.
为增强ROS生产和癌症治疗设计纳米粒子 (NP^BBTPA).
评估NP^BBTPA在触发细胞死亡和抗瘤免疫方面的治疗潜力.

主要方法:

合成了一种具有AIE特征的新型甲衍生物 (BBTPA).
同组装的BBTPA与ROS响应聚合物 (PMD) 和DSPE-PEG2000一起形成BBTPA纳米粒子 (NP).
研究了在超声波暴露时产生的ROS,线粒体损伤,热细胞死亡和免疫细胞死亡 (ICD) 诱导.

主要成果:

BBTPA展示了AIE,克服了ACQ的限制.
在超声波下,NP^BBTPA有效地产生ROS,诱导线粒体损伤和热细胞死亡.
NP^BBTPA证明了超声波触发的ICD,增强了抗瘤免疫反应.

结论:

开发了一种基于AIE的新型声敏化剂 (BBTPA) 用于高级SDT.
工程纳米粒子 (NP^BBTPA) 显示出有效的癌症治疗的巨大潜力.
这种方法有望通过增强抗瘤免疫力来治疗膀癌症.

关键词:

一个AIEIE.在NIR-II中,我们可以看到NIR-II.热性灭症 (Pyroptosis) 是一种这就是ROSOS ROS.这是SDT SDT.

更多相关视频

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...